Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 279-087-4 | CAS number: 79135-87-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Not harmful/toxic if swallowed
Not harmful/toxic by dermal contact
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- From March the 17th to April the 07th,1989
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- Justification for read across is detailed in section 13.
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- adopted on 24 February, 1987
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga, Sulzfeld, West-Germany
- Age at start of treatment: ca. 7 weeks
- Body weight at start of treatment: maales 201 - 213 g; females 148 - 175 g
- Identification: earmark- Diet: free access to standard pelleted laboratory animal diet; certificate of analysis has been created.
- Water: free access to tap-water; certificate of analysis has been created.
- Acclimatisation: at least 5 days under laboratory conditions.
- Accomodation: housed in groups of five per sex in polycarbonate cages containing purified sawdust as bedding material.
ENVIRONMENTAL CONDITIONS
- Temperature: 21 ± 3 °C
- Humidity: 30 - 70 %
- Air changes: 7.5 - 15 ACH
- Photoperiod: 12 hours dark / day - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- TREATMENT
- Dose volume: 20 ml/kg b.w.
- Dosage preparation: the formulations were prepared immediately prior to dosing. The test substance was weighed into a glass flask on an analytical balance and the vehicle (w/w) was added. Homogeneity of the test substance in vehicle was obtained by a homogeniser. - Doses:
- 5000 mg/kg b.w.
- No. of animals per sex per dose:
- 5 males and 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of mortality observations: periodic intervals on the day of dosing (day 1) and twice daily thereafter for at least 14 days.
- Frequency of weighing: day 1 (pre-administration), 8 and 15.
- Frequency of symptoms observation: periodic intervals on the day of dosing (day 1) and once daily thereafter (except day 9 and 10).
- Necropsy of survivors performed: yes. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Mortality:
- No deaths occured.
- Clinical signs:
- No clinical signs of toxicity or behavioural.
- Body weight:
- One female lost 3 grams in the second week; all other animals showed body weight gain during the study period.
- Gross pathology:
- Macroscopic examination of all animals at termination did not reveal any abnormalities.
- Interpretation of results:
- other: not classified, according to CLP Regulation (EC) No1272/2008
- Conclusions:
- LD50 (male and female) > 5000 mg/kg b.w.
- Executive summary:
The test item was administered to rats of both sexes by oral gavage at 5000 mg/kg body weight, followed by a 15 day observation period. The study was conducted in accordance with the method and procedures outline into the OECD guideline 401.
No mortality occurred during the study period. No clinical signs of toxicity or behavioural changes were seen during the study. Apart from one female that lost 3 grams in the second week, all animals showed body weight gain during the study period.
Macroscopic examination of all animals at termination did not reveal any abnormalities that were considered to have arisen as a result of treatment.
Conclusion
LD50 (male and female) > 5000 mg/kg b.w.
Reference
Individual animal observations
Sex | Dose level [mg/kg b.w.] | Observations | No. Animals showing effect at exposure time of | |||||||||||||||||
Hours | Day | |||||||||||||||||||
0.05 | 2.1 | 3.45 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ||||
Males | 5000 | Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n.a. | n.a. | 0 | 0 | 0 | 0 | 0 | |
Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Females | 5000 | Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n.a. | n.a. | 0 | 0 | 0 | 0 | 0 | |
Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
n.a.: inadvertently, no clinical observations performed |
Individual body weights
Sex | Dose level [mg/kg b.w.] | Animal no. | Body weight [g] on day | Body weight gain [g] at end | ||
1 | 8 | 15 | ||||
M | 5000 | 1 | 206 | 249 | 267 | 67 |
2 | 201 | 242 | 258 | 57 | ||
3 | 213 | 275 | 304 | 91 | ||
4 | 208 | 272 | 293 | 85 | ||
5 | 210 | 274 | 302 | 92 | ||
Mean | 208 | 262 | 285 | 77 | ||
s.d. | 4.5 | 15.7 | 21 | 16.9 | ||
F | 5000 | 6 | 173 | 195 | 212 | 39 |
7 | 175 | 189 | 195 | 20 | ||
8 | 149 | 168 | 172 | 23 | ||
9 | 151 | 177 | 180 | 29 | ||
10 | 148 | 162 | 159 | 11 | ||
Mean | 159 | 178 | 184 | 24 | ||
s.d. | 13.6 | 13.8 | 20.5 | 10.4 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- From March the 24th to April the 07th,1989
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- Justification for read across is detailed in section 13.
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- adopted on 24 February, 1987
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga, Sulzfeld, West-Germany
- Age at start of treatment: ca. 6 weeks
- Weight at start of treatment: males 207 - 239 g; females 162 - 196 g
- Diet: free access to standard pelleted laboratory animal diet; certificate of analysis was create.
- Water: free access to tap-water; certificate of analysis was created.
- Accodomation: housed in groups of five per sex in polycarbonate cages containing purified sawdust as bedding material.
- Acclimation period: at least 5 days under laboratory conditions.
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 3 °C
- Humidity: 30 - 70 %
- Air changes: 7.5 - 15 ACH
- Photoperiod: 12 hours dark daily - Type of coverage:
- occlusive
- Vehicle:
- water
- Details on dermal exposure:
- TEST MATERIAL PREPARATION
The formulations were prepared immediately prior to dosing. The test substance was weighed into a glass flask on an analytical balance and the vehicle (w/w) was added. Homogeneity of the test substance in vehicle was obtained by a homogeniser. Concentration of test substance in vehicle was varied to allow constant dosage volume in terms of ml/kg body weight.
TEST SITE
- Shaving (clipping): one day before treatment; area of ca. 5x7 cm on the back of the animal.
- Application area: 5x5 cm for males; 3.5x5 cm for females.
- Type of wrap: gauze patch fixed to aluminium foil and flexible bandage with drops of petrolatum.
TEST MATERIAL
- Dose level: 2000 mg/kg b.w.
- Vehicle volume applied: 10 ml/kg b.w.
- Removal: by tissue moistoned with tap-water. - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kb b.w.
- No. of animals per sex per dose:
- 5 males
5 females - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of mortality observations: periodic intervals on the day of dosing (day 1) and twice daily thereafter for at least 14 days.
- Frequency of weighing: day 1 (pre-administration), 8 and 15
- Frequency of symptoms observation: periodic intervals on the day of dosing (day 1) and once daily thereafter.
- Frequency of skin irritation observation: described immediately after bandage removal (day 2) and on days 5, 8 and 15.
- Necropsy of survivors performed: yes - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Mortality:
- No deaths occurred.
- Clinical signs:
- All animals were noted as lethargic on the day of dosing. There were no other signs of toxicity or behavioural changes seen over the 15 day observation period.
Red spots were noted on the treated skin surface of three animals. - Body weight:
- All animals showed body weight gain during the study period.
- Gross pathology:
- Macroscopic examination of all animals at termination did not reveal any abnormalities.
- Interpretation of results:
- other: not classified, according to CLP Regulation (EC) No 1272/2008
- Conclusions:
- LD50 (male and female) > 2000 mg/kg b.w.
- Executive summary:
The test article was dermally administered to a group of 5 males and 5 female rats with a single dose of 2000 mg/kg b.w. The study was conducted in accordance with the method and procedures outline into the OECD guideline 402.
No deaths and no clinical signs of toxicity were observed during the observation period, as well as body weight changes. In addition, the macroscopic examination revealed no organ abnormalities.
Conclusion
LD50 (male and female) > 2000 mg/kg b.w.
Reference
Individual animal observations
Sex | Dose level [mg/kg b.w.] | Observations | Animal no. Showing effects at time | ||||||||||||||||||
Hour | Day | ||||||||||||||||||||
0.1 | 2.15 | 4.3 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ||||
M | 2000 | Abnormalities | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n.a. | n.a. | 0 | 0 | 0 | 0 | 0 | |
Lethargy | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n.a. | n.a. | 0 | 0 | 0 | 0 | 0 | |||
Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
F | 2000 | Abnormalities | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n.a. | n.a. | 0 | 0 | 0 | 0 | 0 | |
Lethargy | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n.a. | n.a. | 0 | 0 | 0 | 0 | 0 | |||
Crust in the neck | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | n.a. | n.a. | 0 | 0 | 0 | 0 | 0 | |||
Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
n.a.: inadvertently no clinical signs were recorded |
Individual body weights
Sex | Dose level [mg/kg b.w.] | Body weight [g] on day | Body weight gain [g] at end | ||
1 | 8 | 15 | |||
M | 2000 | 216 | 263 | 306 | 90 |
207 | 232 | 267 | 60 | ||
227 | 260 | 296 | 69 | ||
239 | 273 | 311 | 72 | ||
218 | 259 | 292 | 74 | ||
Mean | 221 | 257 | 294 | 73 | |
S.d. | 12.1 | 15.2 | 17.1 | 10.9 | |
F | 2000 | 162 | 182 | 202 | 40 |
196 | 209 | 214 | 18 | ||
189 | 208 | 229 | 40 | ||
178 | 191 | 208 | 30 | ||
174 | 190 | 199 | 25 | ||
Mean | 180 | 196 | 210 | 31 | |
S.d. | 13.2 | 11.9 | 11.9 | 9.6 |
Incidence of treated skin abnormalities
Dose level [mg/kg b.w.] | Observations | Day of evaluation | |||||||
2 | 5 | 8 | 15 | ||||||
M | F | M | F | M | F | M | F | ||
2000 | Abnormalities | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Animals with red spots | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
ACUTE TOXICITY BY ORAL ROUTE
The acute oral toxicity of Optical Brightener 380 was tested using 5 males and 5 females Wistar rats, which were dosed at 15000 mg/kg bw, by oral gavage. On the basis of a preliminary test outcomes, the main test was conducted at the limit dose of 15000 mg/kg bw. No deaths occurred and no signs of poisoning were observed during the observation period of 2 weeks. The body weight gain was normal and no autopsy findings were observed.
Since, the lot tested was characterized by a limited content of Optical Brightener 380, the available experiment conducted on the structural analogous Similar Substance 01 has been taken into consideration, in order to confirm the study outcomes.
The read across approach can be considered reliable and appropriate to investigate the property (details for the approach are included into the IUCLID section 13).
Similar Substance 01 was administered to rats of both sexes by oral gavage at 5000 mg/kg body weight, followed by a 15 day observation period. The study was conducted in accordance with the method and procedures outline into the OECD guideline 401. No mortality occurred during the study period. No clinical signs of toxicity or behavioural changes were seen during the study. Apart from one female that lost 3 grams in the second week, all animals showed body weight gain during the study period. Macroscopic examination of all animals at termination did not reveal any abnormalities that were considered to have arisen as a result of treatment.
ACUTE TOXICITY - INHALATION ROUTE
No acute toxicity studies by inhalation route are available on Optical Brightener 380. Nevertheless, because of the physical state and the trade forms of the substance under registration, inhalation is not an appropriate route of exposure. Acute toxicity results for the other exposure routes indicate no concern.
ACUTE TOXICITY BY DETRMAL ROUTE
Since, no specific experimental is are available on dermal acute toxicity potential of Optical Brightener 380, the available experiment conducted on the structural analogous Similar Substance 01 has been taken into consideration. The read across approach can be considered reliable and appropriate to investigate the property (details for the approach are included into the IUCLID section 13).
Similar Substance 01 was dermal administered to a group of 5 males and 5 female rats with a single dose of 2000 mg/kg bw. The study was conducted in accordance with the method and procedures outline into the OECD guideline 402. No deaths and no clinical signs of toxicity were observed during the observation period, as well as body weight changes. In addition, the macroscopic examination revealed no organ abnormalities.
Justification for classification or non-classification
According to the CLP Regulation (EC) No 1272/2008, 3.1 acute toxicity section, acute toxicity means those adverse effects occurring following oral or dermal administration of a single dose of a substance or a mixture, or multiple doses given within 24 hours, or an inhalation exposure of 4 hours. Substances can be allocated to one of four toxicity categories based on acute toxicity by the oral, dermal or inhalation route according to the numeric criteria. Acute toxicity values are expressed as (approximate) LD50 (oral, dermal) or LC50 (inhalation) values or as acute toxicity estimates (ATE).
The oral LD50 value was established to be greater than 2000 mg/kg body weight, therefore the test substance is out of any classification limit for acute oral toxicity (oral acute toxicity category 4: 300 < ATE ≤ 2000 mg/kg bw).
Dermal LD50 value was established to be greater than 2000 mg/kg body weight, therefore the test substance is out of any classification limit for acute dermal toxicity (dermal acute toxicity category 4: 1000 < ATE ≤ 2000 mg/kg bw).
In conclusion, the substance is not classified for oral, nor dermal acute toxicity, according to the CLP Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.